General Information of Drug (ID: DMDT5JI)

Drug Name
Phenylpyridine derivative 3 Drug Info
Synonyms PMID25416646-Compound-Figure5-G
Cross-matching ID
TTD Drug ID
DMDT5JI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ANGIOTENSIN II DMLWQ27 Increase blood pressure BA04 Approved [2]
SARALASIN DMKS1DV Hypertension BA00-BA04 Approved [3]
EMA-401 DMYOUB6 Peripheral neuropathy 8C0Z Phase 2 [4]
MP-157 DM5VXWO Hypertension BA00-BA04 Phase 1 [5]
PMID25416646-Compound-Figure5-E DMYO7VH N. A. N. A. Patented [1]
1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1 DMGYZQ2 N. A. N. A. Patented [1]
Fonsartan DM15LAP Hypertension BA00-BA04 Discontinued in Phase 2 [6]
L-158282 DMKSEIY N. A. N. A. Discontinued in Phase 2 [7]
TAK-591 DM25DB4 Hypertension BA00-BA04 Discontinued in Phase 1 [8]
L-159689 DM9JE7Y Hypertension BA00-BA04 Terminated [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [10]
Pioglitazone DMKJ485 Amyotrophic lateral sclerosis 8B60.0 Approved [11]
Lobeglitazone DMHY3IP Type-2 diabetes 5A11 Approved [12]
Rosiglitazone XR DMT45MU Type-2 diabetes 5A11 Approved [13]
Thiazolidinedione DMC1NBW Alzheimer disease 8A20 Approved [11]
Glitazone DMDN4A1 N. A. N. A. Phase 4 [14]
MURAGLITAZAR DMG3NFZ N. A. N. A. Phase 3 [15]
Rivoglitazone DMBY31K Ocular inflammation 9C61.24 Phase 3 [16]
Balaglitazone DMXBHR6 Type-1 diabetes 5A10 Phase 3 [17]
Ragaglitazar DMFSHEM Type-1 diabetes 5A10 Phase 3 [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiotensin II receptor type-2 (AGTR2) TTQVOEI AGTR2_HUMAN Agonist [1]
Peroxisome proliferator-activated receptor gamma (PPAR-gamma) TTZMAO3 PPARG_HUMAN Agonist [1]

References

1 PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
2 The preparation of (perfluoroalkyl)imidazoles as nonpeptide angiotensin II receptor antagonists, Bioorg. Med. Chem. Lett. 3(5):895-898 (1993).
3 cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
4 Clinical pipeline report, company report or official report of Spinifex.
5 As drug target reemerges, the question is to block or stimulate it. Nature Medicine. Spoonful of Medicine. 05 Feb 2014. Cassandra Willyard
6 Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. J Hypertens. 1998 Dec;16(12 Pt 2):2039-43.
7 Subtituted phenylthiophene benzoylsulfonamides with potent binding affinity to angiotensin II AT1 and AT2 receptors, Bioorg. Med. Chem. Lett. 4(1):189-194 (1994).
8 Clinical pipeline report, company report or official report of Takeda (2009).
9 The design, binding affinity prediction and synthesis of macrocyclic angiotensin II AT1 and AT2 receptor antagonists, Bioorg. Med. Chem. Lett. 6(8):923-928 (1996).
10 Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602.
11 Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7.
12 Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
13 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
14 Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
15 Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
16 A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806-13.
17 Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma () agonist.Mini Rev Med Chem.2012 Feb;12(2):87-97.
18 Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.